Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Acceptance and Commitment Therapy for Mesh Injury: A HSCED Series

11. november 2026 oppdatert av: University of Lincoln

The Mesh Scandal: Acceptance and Commitment Therapy for Psychological Distress in Mesh Injured Women. A Hermeneutic Single-Case Efficacy Design Series.

The Patient Safety Commissioner estimates that at least 10,000 women in England have experienced significant harm resulting from vaginal mesh implants. Adverse effects resulting in psychological distress and reduced quality of life have been reported. The purpose of the study is to explore the efficacy of Acceptance and Commitment Therapy (ACT) for women with mesh injury experiencing psychological distress.

The study will use a Hermeneutic Single-Case Efficacy Design to answer the primary and secondary objectives.

Primary objective: To investigate whether ACT is an effective therapeutic intervention for women experiencing psychological distress due to mesh injury.

Secondary objectives: To determine whether there are any meaningful changes throughout the ACT intervention; whether these changes can be attributed to the ACT intervention and what factors contribute to the changes.

Participants will undergo a ten-session ACT intervention and follow-up session. A qualitative interview will be carried out to explore the change experience.

Studieoversikt

Detaljert beskrivelse

NICE guidelines recognise the physical and psychological impact of mesh complications and recommends that psychological and psychosexual support is offered to women affected. Despite this, a therapeutic intervention for mesh complications has not yet been explored. Acceptance and Commitment Therapy (ACT) as been empirically supported for its use with populations with long term health conditions.

The study will use a hermeneutic single-case efficacy design and evaluate the process of change during the intervention. Following the ACT intervention, rich case records for each participant will be created using quantitative and qualitative data; this data will consist of demographic data, outcome measures and therapy material. The rich case records will be cross-referenced and amalgamated into an "affirmative" brief that presents evidence that the change can be attributed to the therapeutic intervention. The rich case record will also be analysed for indirect evidence to develop a "skeptic" brief, a brief presenting an alternative explanation for the therapeutic change. Both analyses will be evaluated through a presentation of both briefs, a rebuttal of the opposing brief and a summary narrative . The adjudication process will be overseen by three independent judges who will evaluate the rich case records and briefs to provide an outcome ; whether there has been a change during the therapeutic intervention and whether the therapeutic intervention was a key influence on this outcome.

Studietype

Intervensjonell

Registrering (Antatt)

6

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Beskrivelse

Inclusion Criteria:

Woman aged 18 or over.

  • Registered with a UK GP.
  • Currently under the care of or recently discharged from Nottingham or Manchester Complex Mesh Centres or have contacted their GP about mesh complications.
  • Has had surgery for Stress Urinary Incontinence (SUI) and/or Pelvic Organ Prolapse (POP) and has or have had implanted polypropylene mesh causing complications.
  • Experiencing self-reported psychological distress.
  • Able to communicate in English.
  • Has access to a device with internet access.
  • Willing and able to provide informed consent for participation in the study.
  • Willing to engage in psychological therapy.

Exclusion Criteria:

  • ACT intervention in the past twelve months due to the potential impact on the efficacy of the therapeutic intervention and to reduce cofounding variables.
  • Currently engaging in psychological therapy due to the potential impact on the efficacy of the therapeutic intervention and to reduce cofounding variables.
  • Have insufficient command of the English language due to resources and potential impact of an interpreter on mechanism of change.
  • Significant cognitive impairment.
  • Current suicidal ideation for ethical and safety reasons.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Acceptance and Commitment Therapy

Participants will receive a ten-session Acceptance and Commitment Therapy (ACT) intervention

Acceptance and commitment therapy (ACT) is a "third wave" Cognitive Behavioural Therapy that focuses on increasing psychological flexibility and acceptance of difficult experiences by undertaking value-drive actions despite psychological suffering. Psychological flexibility is developed and expanded through six core processes: acceptance, defusion, present moment awareness, self-as-context, values and committed action.

Adherence to a strict protocol is not mandated for an ACT intervention; the study will be informed by an adapted ACT intervention for chronic pain (Scott et al., 2018). The intervention will reflect the heterogenous nature of mesh injury.

The intervention will consist of ten individual weekly sessions lasting up to 60 minutes.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Hermeneutic Single-Case Efficacy Design - adjudication
Tidsramme: Through study completion, an average of 9 months.

The adjudication process will be overseen by three independent judges who will evaluate the rich case records and briefs to provide an outcome ; whether there has been a change during the therapeutic intervention and whether the therapeutic intervention was a key influence on this outcome (Elliott et al., 2009).

Through study completion, an average of 9 months.
Psychological distress assessed using the Clinical Outcomes in Route Evaluation 10 (CORE-10; Barkham et al., 2013)
Tidsramme: From baseline to the end of treatment, up to 16 weeks.

10-item measure designed to measure common presentations of psychological distress. The minimum value is 0 and the maximum value is 40. A higher score indicates severe distress.

From baseline to the end of treatment, up to 16 weeks.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Mesh symptoms impact on quality of life assessed using the International Consultation on Incontinence Questionnaire Lower Urinary Tract Symptoms Quality of Life (ICIQ-LUTSqol; Kelleher et al., 1997)
Tidsramme: From baseline to the end of treatment, up to 16 weeks.

20-item measure designed to measure the physical, emotional, social, and practical impact of urinary symptoms. Measure adapted to assess "mesh problem" instead of "urinary problem" (Brown, 2020). The minimum value is 0 and the maximum value is 76. A higher score indicates greater impact on quality of life.

From baseline to the end of treatment, up to 16 weeks.
Psychological flexibility assessed using the Comprehensive assessment of Acceptance and Commitment Therapy Processes (CompACT-10; Golijani-Moghaddam et al., 2023)
Tidsramme: From baseline to the end of treatment, up to 16 weeks.

10-item short-form version of the Comprehensive Assessment of Acceptance and Commitment Therapy Processes (CompACT), designed to measure psychological flexibility and its core sub-processes. The minimum value is 0 and the maximum value is 60. A higher score indicates greater level of psychological flexibility.

From baseline to the end of treatment, up to 16 weeks.
Therapeutic alliance assessed using the Session Rating Scale (SRS; Duncan et al., 2003)
Tidsramme: Weekly during the therapy intervention, up to 10 weeks.

4-item measure designed to measure the quality of the therapeutic alliance. The minimum value is 0 and the maximum value is 40. A higher score indicates greater therapeutic alliance.

Weekly during the therapy intervention, up to 10 weeks.
Client's perception of therapy sessions assessed using the Helpful Aspects of Therapy (HAT; Llewelyn, 1988)
Tidsramme: Weekly during the therapy intervention, up to 10 weeks.

A measure designed to identify specific events that participants found most helpful during the therapy session. The minimum value is 1 and the maximum value is 9 for each scale. A higher score indicates greater helpful impact.

Weekly during the therapy intervention, up to 10 weeks.
Change in client's goals assessed using the Personal Questionnaire (PQ; Elliott et al., 1999)
Tidsramme: Weekly during the therapy intervention, up to 10 weeks.

A measure personalised to the participant, identifying problems that the participant would like to work on in therapy. The minimum value is 7 and the maximum value is 91 for each scale. A higher score indicates greater progress towards goals/problem identified at the start of therapy.

Weekly during the therapy intervention, up to 10 weeks.
Adherence to ACT processes measured using the Acceptance and Commitment Therapy Fidelity Measure (ACT-FM; O'Neill et al., 2019)
Tidsramme: During the therapy intervention for up to 10 weeks.

A measure of therapist fidelity in delivering Acceptance and Commitment Therapy. The minimum value is 0 and the maximum value is 36 for ACT consistent and ACT inconsistent subscales. A higher score for the ACT consistent subscale indicates adherence to ACT processes.

During the therapy intervention for up to 10 weeks.
Client's perception of therapy intervention and change processes assessed using the Client Change Interview (Elliott et al., 2001)
Tidsramme: Within two weeks of end of therapy intervention, at 12 weeks.

A semi-structured interview to explore the mechanism of change.

Within two weeks of end of therapy intervention, at 12 weeks.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Danielle De Boos, ClinPsyD, University of Nottingham

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. desember 2026

Primær fullføring (Antatt)

1. august 2027

Studiet fullført (Antatt)

1. august 2027

Datoer for studieregistrering

Først innsendt

5. november 2026

Først innsendt som oppfylte QC-kriteriene

11. november 2026

Først lagt ut (Faktiske)

18. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

11. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

The results of the research study will be submitted in partial fulfilment of doctoral thesis in Clinical Psychology. A journal manuscript will be submitted to a peer-reviewed journal and any data submitted will be anonymised. Any published outputs will contain a data availability statement linked to the repository. The full dataset and any special category data will not be publicly available due to participant privacy.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere